Quick answer: Nextech's built-in prior authorization automation handles auto-flagging, electronic submission, and basic data pull for ePA-eligible payers, while third-party AI prior authorization agents add intelligent clinical-data extraction, payer-rule learning across hundreds of plans, denial prediction, and human-in-the-loop handling for edge cases the native rules engine doesn't cover. For multi-specialty groups and PE-backed MSOs with high PA volume, the answer is usually both — Nextech for the routine workflow, the AI agent on top for the long tail. The right comparison isn't which one to pick; it's where the handoff between them belongs.
What Nextech's built-in prior authorization does well
Nextech's prior authorization automation is built around the order-entry flow inside the EHR, and it does four things reliably: it flags procedures and medications that require PA at the point of order, it pre-populates the PA submission with patient demographics and clinical data from the chart, it submits electronically through the ePA module for payers that support electronic prior authorization, and it tracks status inside the auth team's work queue.
For the workflow that fits cleanly inside those four capabilities, Nextech's native automation works well. The cost is bundled into the Nextech RCM module subscription, the integration depth is native (no separate platform to deploy, no interface engine to maintain), and the auth team operates in one system without switching contexts. For specialty practices on Nextech with a payer mix that's mostly ePA-eligible and a procedure catalog that maps cleanly to Nextech's rule library, the native automation handles the bulk of the PA workload.
The math at this baseline is real. For a typical specialty practice running 40 PAs per physician per week — the AMA's prior authorization survey puts staff PA effort at roughly 13–16 hours per week — Nextech's ePA module typically recovers 50–60% of that effort by automating the data assembly and submission steps. That's not the full benefit available, but it's the part that doesn't require a separate vendor relationship or a separate budget line.
The question for multi-specialty groups and MSOs is whether 50–60% is enough.
Where third-party AI agents extend Nextech
Third-party AI prior authorization agents — running alongside Nextech rather than replacing it — add four capabilities on top of what Nextech ships natively. The capabilities are what close the gap between Nextech's coverage and what the practice actually needs.
Multi-payer rule modeling across hundreds of plans. Nextech's rule library handles the major commercial payers and Medicare Advantage plans well. The long tail — smaller commercial plans, state Medicaid managed care variations, worker's comp carriers, niche specialty plans — is where the library has gaps. AI agents that ingest payer policy documents and model the rules across hundreds of plans cover that long tail without waiting for Nextech's library updates.
Intelligent clinical-data extraction. Beyond the demographics and basic clinical fields Nextech pulls from the chart, AI agents can read the encounter note, the prior treatment history, the imaging report, and the lab results to identify exactly which clinical evidence the payer's policy requires for that specific PA. The difference shows up at the denial rate — submissions assembled with the right clinical evidence on the first pass get denied less often than submissions assembled with the standard data pull.
Denial prediction. AI agents can flag submissions likely to be denied before they go out, so the team can add the right documentation upfront rather than fighting an appeal after the denial. This is the capability that compounds over time, because every denial avoided removes a peer-to-peer call or appeal from the workflow.
Human-in-the-loop handling for edge cases. When a PA submission requires judgment — ambiguous clinical criteria, novel payer policies, a peer-to-peer call that needs specific clinical evidence prepared — the AI agent surfaces the case for human review with the context already gathered. Strong AI agents put the reviewer in a 30-second decision instead of a 30-minute investigation.
These four capabilities are what defines the third-party AI agent as a layer on top of Nextech rather than a replacement for it.
The decision matrix by practice size and PA volume
The decision between Nextech alone and Nextech plus an AI agent comes down to where your practice sits on three variables: PA volume, payer mix complexity, and the operational cost of denied PAs.
Single-specialty practice under 10 providers, mostly ePA-eligible payer mix, low denial rate. Nextech's native PA automation is probably enough. The PA volume isn't high enough to stress the auth team, the rule library covers most of the payer mix, and the denial volume doesn't justify the cost of an additional vendor relationship.
Multi-specialty group with 10–25 providers, mixed ePA and non-ePA payers, moderate denial rate. The decision gets harder. The PA volume is high enough that even Nextech's automation leaves meaningful workload on the auth team. The payer mix includes some plans Nextech doesn't model deeply. The denial rate is uncomfortable but not yet a crisis. Most practices in this segment evaluate the AI agent and choose based on whether they're planning to extend automation to other back-office workflows in the next 12–18 months.
PE-backed MSO or multi-specialty group with 25+ providers and significant non-ePA payer share. The AI agent on top of Nextech is usually the right answer. PA volume at this scale outgrows the auth team's capacity even with Nextech's automation. The non-ePA payer share generates manual work that doesn't scale. Denial-driven AR becomes a meaningful category of aged receivables that the AI agent's denial prediction capability addresses directly.
Any practice where PA-driven AR is the largest single category of aged receivables. Regardless of size, if PA denials are the bottleneck in cash collection, the AI agent's denial prediction and appeal-prep capabilities usually pay for themselves quickly.
The matrix isn't sharp at the edges. A 12-provider single-specialty practice with heavy biologics and a complicated payer mix can be closer to the MSO end of the spectrum than the headcount suggests. Use volume and complexity, not provider count alone.
The hidden cost of running both without a clear handoff
Running Nextech's native PA automation and a third-party AI agent in parallel without a clear handoff between them is a real failure mode that operators should plan around explicitly.
The failure mode is double-handling. The native automation flags a PA, pre-builds a submission, and routes it to the auth team's queue. The AI agent also picks up the order, builds its own submission, and routes a different version of the same PA. The auth team ends up reviewing two versions of every PA, deciding which one to use, and losing the time savings the automation was supposed to deliver.
The fix is a clear ownership boundary. Either the native automation handles a defined subset of PA traffic (ePA-eligible major payers with simple clinical criteria) and the AI agent handles the rest, or the AI agent handles everything and writes back into Nextech's queue with a single PA submission per order. The second pattern is usually cleaner because it removes the operational ambiguity, but both work as long as the ownership boundary is unambiguous.
This is the part of the layered deployment that requires deliberate design rather than a procurement decision. The vendor selection determines whether the integration is technically possible; the ownership boundary determines whether the integration actually saves time.
How to evaluate the layered approach honestly
Three questions cut through vendor marketing during a third-party AI PA agent evaluation.
What does the agent do that Nextech doesn't already do? A vendor that says "we automate prior authorization" without specifying which capabilities they add on top of Nextech's existing automation is probably selling overlap, not extension. Ask for a feature-by-feature comparison against Nextech's native ePA module — multi-payer rule depth, clinical-data extraction depth, denial prediction, non-ePA channel coverage, peer-to-peer support. If the agent and Nextech overlap on most of these without clear extension in any of them, the agent isn't adding the value the rollout needs.
Does the agent write back into Nextech, or does it expect the auth team to switch systems? Strong AI PA agents write PA status back into the Nextech work queue so the auth team operates in one place. Weak ones force the team to log into a separate UI, which fragments the workflow and erodes the time savings.
How does the vendor handle the long tail of non-ePA payers? This is usually the biggest functional gap in Nextech's native automation. An AI agent that handles ePA only is mostly redundant with Nextech; one that handles portal, fax, and phone submission for the non-ePA payer mix is where the real extension happens. Ask specifically about non-ePA payer coverage and the workflow for each channel.
Honey Health's Prior Authorization agent is the canonical example of the third-party AI layered pattern for Nextech practices. The agent reads orders from Nextech, applies its own payer-rule and clinical-criteria modeling across hundreds of plans (including the non-ePA long tail), handles submission across ePA, portal, fax, and phone channels, and writes PA status back into the Nextech work queue. The same architecture extends across eligibility verification, denial management, refill management, fax triage, and payment posting, so practices adopting AI PA automation as the first step can extend automation across the rest of the back office without changing vendors.
When Nextech alone is the right answer
Three signals tell you Nextech's built-in PA automation is enough on its own and a third-party AI agent isn't worth the investment yet:
- Your PA volume is 25 or fewer per provider per week and your auth team isn't running constant overtime.
- 80%+ of your PA volume is concentrated in major commercial payers and Medicare Advantage plans that Nextech's rule library handles well.
- Your PA-related denial rate is below 8% and PA-driven AR isn't a major category of aged receivables.
When all three signals point toward "Nextech alone is enough," the AI agent on top is usually a premature investment. The native automation is doing its job; adding a layer doesn't have a clear bottleneck to address.
The signals to revisit the decision are usually: PA volume growing as the practice adds providers, payer mix shifting toward more non-ePA plans (worker's comp expansion, Medicaid managed care growth), or denial rates trending up because Nextech's rule library is falling behind payer policy changes. When any of those start to show up, the layered AI agent becomes worth evaluating.
Frequently asked questions
Will running both Nextech's PA automation and a third-party AI agent double our PA submissions?
It shouldn't, if the integration is configured correctly. The standard pattern is that the AI agent owns the PA submission for orders within its scope, and Nextech's native automation owns the rest. Both write status back into the same work queue inside Nextech. The auth team sees one submission per order; the underlying system handling the submission depends on the order's payer and clinical context.
How much does adding a third-party AI PA agent typically cost on top of Nextech?
Pricing varies by vendor, but most AI PA agents in 2026 price either per PA submission (typically $3–$8 per submission) or per provider per month ($150–$400 depending on tier and volume). For a 15-provider specialty practice with high PA volume, total annual cost typically lands in the $40,000–$90,000 range. The ROI math depends on the auth team labor recovered, the denial rate reduction, and the recovered revenue from faster start-of-care.
Does the AI agent integration require any changes to Nextech configuration?
Usually minimal. The AI agent typically integrates through Nextech's API or HL7 channel to read orders and write status updates. The auth team's work queue and routing rules stay the same; the agent just appears as a new source of submissions and status updates within the existing queue. Implementation timelines for the integration typically run 4–8 weeks depending on the vendor and the specific payer mix being covered.
How long does it take to see ROI from layering an AI agent on top of Nextech's automation?
Most practices see meaningful payback in 3–6 months when the layered approach is properly configured. The labor savings start showing up in week 1; the denial rate reduction takes 2–3 months to surface in the data; the recovered revenue from faster start-of-care shows up over 60–90 days as faster cash collection. Practices with PA-driven AR as a major bottleneck typically see payback faster because the denial prediction capability addresses the bottleneck directly.
Can we trial a third-party AI agent on a subset of payers before committing?
Yes, and most vendors support it. The standard trial pattern is to run the AI agent on 2–4 payers (often the non-ePA payers Nextech doesn't fully cover) for 60–90 days while keeping Nextech's native automation for the rest of the payer mix. The trial gives the auth team time to validate the agent's submission quality and the practice time to measure the impact on denials and PA-driven AR before scaling to the full payer mix.
